IMPEL PHARMACEUTICALS INC (IMPL) Stock Fundamental Analysis

NASDAQ:IMPL • US45258K1097

0.2411 USD
-0.17 (-41.79%)
At close: Dec 15, 2023
0.22 USD
-0.02 (-8.75%)
After Hours: 12/15/2023, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, IMPL scores 1 out of 10 in our fundamental rating. IMPL was compared to 521 industry peers in the Biotechnology industry. Both the profitability and financial health of IMPL have multiple concerns. IMPL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • IMPL had negative earnings in the past year.
  • IMPL had a negative operating cash flow in the past year.
IMPL Yearly Net Income VS EBIT VS OCF VS FCFIMPL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

  • IMPL has a worse Return On Assets (-204.40%) than 92.36% of its industry peers.
Industry RankSector Rank
ROA -204.4%
ROE N/A
ROIC N/A
ROA(3y)-194.15%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMPL Yearly ROA, ROE, ROICIMPL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -1K -2K

1.3 Margins

  • IMPL has a better Gross Margin (57.30%) than 80.07% of its industry peers.
  • The Profit Margin and Operating Margin are not available for IMPL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMPL Yearly Profit, Operating, Gross MarginsIMPL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • IMPL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IMPL has more shares outstanding
  • Compared to 1 year ago, IMPL has a worse debt to assets ratio.
IMPL Yearly Shares OutstandingIMPL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 5M 10M 15M 20M
IMPL Yearly Total Debt VS Total AssetsIMPL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -18.82, we must say that IMPL is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -18.82, IMPL is doing worse than 89.37% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.82
ROIC/WACCN/A
WACC10.15%
IMPL Yearly LT Debt VS Equity VS FCFIMPL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 0.27 indicates that IMPL may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.27, IMPL is doing worse than 97.01% of the companies in the same industry.
  • A Quick Ratio of 0.21 indicates that IMPL may have some problems paying its short term obligations.
  • IMPL has a Quick ratio of 0.21. This is amonst the worse of the industry: IMPL underperforms 97.34% of its industry peers.
Industry RankSector Rank
Current Ratio 0.27
Quick Ratio 0.21
IMPL Yearly Current Assets VS Current LiabilitesIMPL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • IMPL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.50%.
  • IMPL shows a strong growth in Revenue. In the last year, the Revenue has grown by 264.05%.
EPS 1Y (TTM)3.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.1%
Revenue 1Y (TTM)264.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%135%

3.2 Future

  • IMPL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.33% yearly.
  • IMPL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 87.95% yearly.
EPS Next Y64.5%
EPS Next 2Y34.33%
EPS Next 3Y23.19%
EPS Next 5Y21.33%
Revenue Next Year128.2%
Revenue Next 2Y101.18%
Revenue Next 3Y85.83%
Revenue Next 5Y87.95%

3.3 Evolution

IMPL Yearly Revenue VS EstimatesIMPL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
IMPL Yearly EPS VS EstimatesIMPL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • IMPL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMPL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMPL Price Earnings VS Forward Price EarningsIMPL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMPL Per share dataIMPL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMPL's earnings are expected to grow with 23.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.33%
EPS Next 3Y23.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IMPL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

IMPEL PHARMACEUTICALS INC

NASDAQ:IMPL (12/15/2023, 8:00:03 PM)

After market: 0.22 -0.02 (-8.75%)

0.2411

-0.17 (-41.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners11.64%
Inst Owner Change-0.05%
Ins Owners25.56%
Ins Owner Change0%
Market Cap5.76M
Revenue(TTM)19.04M
Net Income(TTM)-91.57M
Analysts80
Price Target40.8 (16822.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-33.53%
Min EPS beat(2)-38.34%
Max EPS beat(2)-28.72%
EPS beat(4)1
Avg EPS beat(4)-20.14%
Min EPS beat(4)-38.34%
Max EPS beat(4)14.63%
EPS beat(8)1
Avg EPS beat(8)-21.64%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.01%
Min Revenue beat(2)-25.27%
Max Revenue beat(2)-0.75%
Revenue beat(4)0
Avg Revenue beat(4)-18.82%
Min Revenue beat(4)-48.17%
Max Revenue beat(4)-0.75%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)99900%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.41
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-3.65
FCFYN/A
OCF(TTM)-3.57
OCFYN/A
SpS0.8
BVpS-3.31
TBVpS-3.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -204.4%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.3%
FCFM N/A
ROA(3y)-194.15%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 252.44%
Cap/Sales 10.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.27
Quick Ratio 0.21
Altman-Z -18.82
F-Score4
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)105.81%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.1%
EPS Next Y64.5%
EPS Next 2Y34.33%
EPS Next 3Y23.19%
EPS Next 5Y21.33%
Revenue 1Y (TTM)264.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%135%
Revenue Next Year128.2%
Revenue Next 2Y101.18%
Revenue Next 3Y85.83%
Revenue Next 5Y87.95%
EBIT growth 1Y14.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.28%
EBIT Next 3Y18.34%
EBIT Next 5YN/A
FCF growth 1Y-86.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.11%
OCF growth 3YN/A
OCF growth 5YN/A

IMPEL PHARMACEUTICALS INC / IMPL FAQ

What is the fundamental rating for IMPL stock?

ChartMill assigns a fundamental rating of 1 / 10 to IMPL.


What is the valuation status for IMPL stock?

ChartMill assigns a valuation rating of 1 / 10 to IMPEL PHARMACEUTICALS INC (IMPL). This can be considered as Overvalued.


How profitable is IMPEL PHARMACEUTICALS INC (IMPL) stock?

IMPEL PHARMACEUTICALS INC (IMPL) has a profitability rating of 1 / 10.


How financially healthy is IMPEL PHARMACEUTICALS INC?

The financial health rating of IMPEL PHARMACEUTICALS INC (IMPL) is 0 / 10.


What is the earnings growth outlook for IMPEL PHARMACEUTICALS INC?

The Earnings per Share (EPS) of IMPEL PHARMACEUTICALS INC (IMPL) is expected to grow by 64.5% in the next year.